


Research Center Uganda

Conducting clinical research to address health issues in African region



- Located within Mbarara University of Science and Technology (MUST) and Mbarara Regional Referral Hospital (MRRH).
- Activity initiated in 1996 in Mbarara, Southwestern Uganda
- Site for high-profile multi-centric trials for over 20 years
- An experienced team of over 100 medical doctors, epidemiologists, statisticians, biologists, lab technologists, IT and data managers, research quality officers, nurses...
- **Laboratory:** Accreditation GCLP (Good Clinical Laboratory Practice) and biosafety level 3 ; equipped for microbiology, biochemistry, hematology and molecular biology tests (classical PCR, real-time qPCR, GeneXpert, PCR test for SARS-COV2).
- **Expertise on several infectious diseases:** malaria, Ebola, yellow fever, tuberculosis, central nervous system infections.
- In close collaboration with MSF



IMPROVING ACCESS TO CARE AND HEALTH FOR THE MOST VULNERABLE POPULATIONS

2007-2010

AQUAMAT: Evidence of significant reduction in mortality with artesunate in African children with severe malaria.



2019

Evaluation of 4-in-1 treatment, a combination of 4 drugs in a single, easy-to-use, heat-stable, tasteless, solid capsule for children with HIV in Uganda.

2019-2022

Site for the RIFASHORT study which investigated benefit of increasing Rifampicin dose in shortening treatment duration for Tuberculosis.




2019-2022

Site for studies in the TB-speed project, which aims to reduce mortality by improving tuberculosis diagnosis in children.

2019-2023

Demonstration of the feasibility of using fractional doses of yellow fever vaccine in adult, children and HIV infected adults.



2018-2023

Participation in the EDCTP-funded DNDi trial that evaluates efficacy and safety of fexinidazole in patients with Trypanosoma brucei rhodesiense (r-THA).

2022-2023

MSF Ebola outbreak supported




2019-2022

ZEBOVAC : Evaluation of the safety and immunogenicity of the Ebola vaccination schedule of the Ad26.ZEBOV/MVA-BN®-Filo vaccine

2023-2024

Site for DATURA which is investigating the impact of intensifying the initial TB treatment phase on mortality



2023-2025

Tb-Algo Evaluation of the effectiveness and acceptability of two treatment decision algorithms for TB in children

Our competencies

Research unit

- Medical,
- Data management & IT
- Monitoring and Quality Control

Laboratory unit

- Biologists (quality management, biosafety)
- lab technologists and technicians

Support unit

- Administrative, human resources, finance, logistics



Building capacities in the country and regional integration

Long term investment in the country and contributing to improve research and healthcare

Qualified local investigators with experience in prevailing health conditions eg TB

Clinical trials module of MPH and Bachelor of Lab Science at MUST

Laboratory support for MDR-TB activities, COVID-19

Development of Research Guidelines and tools (Post-trial access guidelines, Community engagement guidelines)

